SPPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-05-05), Spectrum Pharmaceuticals's Intrinsic Value: Projected FCF is $-4.52. The stock price of Spectrum Pharmaceuticals is $1.03. Therefore, Spectrum Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for Spectrum Pharmaceuticals's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Spectrum Pharmaceuticals was 109.38. The lowest was 0.00. And the median was 2.11.
The historical data trend for Spectrum Pharmaceuticals's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectrum Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | 0.08 | -2.40 | -3.53 | -4.85 | -4.44 |
Spectrum Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Intrinsic Value: Projected FCF | Get a 7-Day Free Trial | -4.82 | -4.90 | -4.56 | -4.44 | -4.52 |
For the Biotechnology subindustry, Spectrum Pharmaceuticals's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Spectrum Pharmaceuticals's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)
In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):
Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)
Add all the Free Cash Flow together and divide 6 will get Spectrum Pharmaceuticals's Free Cash Flow(6 year avg) = $-98.21.
Spectrum Pharmaceuticals's Intrinsic Value: Projected FCF for today is calculated as
Intrinsic Value: Projected FCF | = | (Growth Multiple | * | Free Cash Flow (6 year avg) | + | Total Stockholders Equity (Mar23) | * | 0.8) | / | Shares Outstanding (Diluted Average) |
= | (9.5203515959648 | * | -98.2096 | + | 26.805 | * | 0.8) | / | 201.918 | |
= | -4.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectrum Pharmaceuticals (NAS:SPPI) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Spectrum Pharmaceuticals's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF | = | Share Price | / | Intrinsic Value: Projected FCF |
= | 1.03 | / | -4.5243411785926 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Juhyun Lim | director | 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Brittany Bradrick | director | C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130 |
William Ashton | director | C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073 |
Nora Brennan | officer: See Remarks | C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355 |
Keith M Mcgahan | officer: Chief Legal Officer | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Thomas J Riga | director, officer: CEO & President | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Jeff L Vacirca | director | 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121 |
Francois Lebel | officer: Chief Medical Officer | 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998 |
Dolatrai Vyas | director | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Kurt A Gustafson | officer: EVP & Chief Financial Officer | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Joseph W. Turgeon | officer: Chief Commercial Officer | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Elizabeth Czerepak | director | 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070 |
Maida Anthony E Iii | director | 157 TECHNOLOGY DR, IRVINE CA 92618 |
Stuart Mitchell Krassner | director | 157 TEHCNOLOGY DRIVE, IRVINE CA 92618 |
From GuruFocus
By sperokesalga sperokesalga • 05-01-2023
By Business Wire Business Wire • 02-03-2023
By PRNewswire PRNewswire • 01-25-2023
By Business Wire Business Wire • 05-17-2023
By PRNewswire PRNewswire • 01-27-2023
By PRNewswire PRNewswire • 01-26-2023
By Stock market mentor Stock market mentor • 01-29-2023
By PRNewswire PRNewswire • 01-31-2023
By PRNewswire PRNewswire • 01-28-2023
By PRNewswire PRNewswire • 02-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.